Valneva Confirms Positive Results of Its Chikungunya Vaccine in Children
Valneva SE has announced the final results of a Phase 2 study on its chikungunya vaccine, IXCHIQ®, demonstrating a robust immune response and good tolerance in children.
According to Valneva SE, the final results of the Phase 2 study, which involved 304 children aged one to eleven years, showed that the IXCHIQ® vaccine was well tolerated regardless of the administered dose or a previous infection by the virus. The data indicate that antibody levels remain high twelve months after vaccination, with a more robust response in the group that received a full dose. A seroresponse rate of 94.7% was observed one year after vaccination in children who had not been previously exposed to chikungunya.
Implications for Future Clinical Trials
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The results support the choice of a full dose for a future Phase 3 clinical trial, which Valneva plans to initiate after gathering additional data in adolescents. The Chief Medical Officer, Juan Carlos Jaramillo, emphasized the importance of ensuring safety before proceeding with the Phase 3 pediatric study. The company aims to make the vaccine accessible in endemic areas, particularly in low- and middle-income countries.
Chikungunya: A Growing Public Health Concern
Chikungunya is a mosquito-borne disease affecting many regions of the world. Among the most affected countries are Brazil and India. According to the World Health Organization, chikungunya poses a significant public health risk due to the geographic expansion of the mosquito vectors. The economic impact of the disease is considerable, and the WHO emphasizes the need for ongoing surveillance.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
